Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Alzheimer's patients face several hurdles if Biogen's Alzheimer's drug is OK'd
Beckers Hospital Review
Wed, 05/26/21 - 11:18 am
Biogen
Alzheimer's disease
aducanumab
FDA
Biogen and Ginkgo Bioworks team up to develop novel gene therapy manufacturing platform
Biopharma Reporter
Mon, 05/24/21 - 10:43 am
Biogen
Ginkgo Bioworks
gene therapy
Biogen gene therapy for rare eye disease falls short in key clinical trial
MedCity News
Sun, 05/16/21 - 11:26 pm
Biogen
gene therapy
clinical trials
X-linked retinitis pigmentosa
cotoretigene toliparvovec
Biogen taps Envisagenics’ AI to speed up RNA splicing R&D
Pharmaforum
Fri, 05/14/21 - 10:44 am
Biogen
RNA
drug discovery
Envisagenics
artificial intelligence
Biogen buys midphase drug to challenge Roche for stroke market
Fierce Biotech
Wed, 05/12/21 - 11:07 am
Biogen
acute ischemic stroke
stroke
TMS
Biogen looks to build better gene therapies through latest deal
BioPharma Dive
Tue, 05/11/21 - 11:45 am
Biogen
gene therapy
Capsigen
Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?
Endpoints
Thu, 05/6/21 - 10:57 am
Biogen
aducanumab
Alzheimer's disease
drug pricing
ICER
Zolgensma flatlines, but Spinraza isn’t the beneficiary
EP Vantage
Wed, 04/28/21 - 10:27 am
SMA
Biogen
Novartis
Roche
Spinraza
Zolgensma
Evrysdi
Following pressure, Biogen to start compassionate use program for ALS drug tofersen
Seeking Alpha
Tue, 04/27/21 - 10:58 am
Biogen
ALS
tofersen
compassionate use guidelines
Biogen's Michel Vounatsos takes home $18.7M in pay as the company battles to take aducanumab to market
Endpoints
Tue, 04/27/21 - 10:48 am
Biogen
Pharma CEOs
Michel Vounatsos
executive pay
aducanumab
Why Biogen's Better-Than-Expected Q1 Results Weren't Good Enough
Motley Fool
Thu, 04/22/21 - 11:09 am
Biogen
earnings
Biogen’s Alzheimer’s hopeful aducanumab faces ‘less than a coin flip’s chance’ of FDA approval: analysts
Fierce Pharma
Wed, 04/21/21 - 11:29 pm
Biogen
aducanumab
Alzheimer's disease
Biogen Reports New Spinraza Data in SMA
Global Genes
Wed, 04/21/21 - 10:34 am
Biogen
Spinraza
SMA
The next 2 months in biotech and pharma will be busy. Here's what to watch.
BioPharma Dive
Tue, 04/20/21 - 11:16 pm
Biogen
aducanumab
FDA
Vertex Pharmaceuticals
Sarepta Therapeutics
JNJ
AstraZeneca
vaccines
COVID-19
A new market beckons for Alzheimer’s blood tests
EP Vantage
Mon, 04/19/21 - 11:12 am
Alzheimer's disease
diagnostics
donanemab
Eli Lilly
Biogen
Quanterix
Quiet times return for biopharma takeouts
EP Vantage
Wed, 04/14/21 - 09:26 am
M&A
Alexion
Amgen
AstraZeneca
Biogen
Five Prime Therapeutics
Gilead Sciences
GW Pharma
Horizon Therapeutics
Immunomedics
Jazz Pharmaceutical
Kymab
Merck
Pandion
Sanofi
Viela Bio
Sage, Biogen's tremor drug hits goal, but 38% of people drop out
Fierce Biotech
Mon, 04/12/21 - 10:36 am
SAGE Therapeutics
Biogen
essential tremor
SAGE-324
side effects
clinical trials
Biogen adds a late-stage prospect to its growing biosimilar business
BioPharma Dive
Thu, 04/8/21 - 07:44 pm
Biogen
Actemra
anti-inflammatories
biosimilars
COVID-19
FDA grew too close to Biogen during Alzheimer’s drug development, doctors say
Pharmaforum
Thu, 04/1/21 - 10:51 am
FDA
Biogen
drug development
aducanumab
Alzheimer's disease
FDA advisers reassert case against approval of Biogen's Alzheimer's drug
BioPharma Dive
Wed, 03/31/21 - 10:55 pm
Biogen
FDA
Alzheimer's disease
aducanumab
Pages
« first
‹ previous
…
17
18
19
20
21
22
23
24
25
…
next ›
last »